Hi-Bio
Clinical trials sponsored by Hi-Bio, explained in plain language.
A Biogen subsidiary developing therapies for immunology and inflammation.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New antibody drug targets kidney damage in lupus patients
Disease control CompletedThis early-stage study tests a drug called felzartamab in 14 people with active lupus nephritis, a kidney condition caused by lupus. The drug is a lab-made antibody designed to lower harmful antibody buildup in the kidneys. The main goal is to check safety and how the drug works …
Phase 1 • Sponsor: HI-Bio, A Biogen Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody drug shows promise for kidney disease
Disease control CompletedThis Phase 2 trial tested a drug called felzartamab in 54 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug targets immune cells to reduce protein leakage in urine, a sign of kidney damage. The study compared felzartamab to a placebo to see i…
Phase 2 • Sponsor: HI-Bio, A Biogen Company • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC